FDA Approved Products

11 products with lifecycle intelligence, competitive pressure scores, and patent timelines.

Type:AllNDABLAANDA
Lifecycle:GrowthPeakLOE ApproachingPost-LOELaunchPre-Launch
Sort:Approval DateNameCompetitive Pressure↓
Active:Lifecycle: Post-LOEClear all
AEMCOLO
rifamycin sodium
Post-LOE
Cosmo Pharmaceuticals
ORAL · TABLET, DELAYED RELEASE
2018
NDA
35/100
BRIVIACT
brivaracetam
Post-LOE
UCB Pharma
INTRAVENOUS · SOLUTION
partial-onset seizures in patients 1 month of ageolder
2016
NDA
35/100
BRIVIACT
brivaracetam
Post-LOE
UCB Pharma
ORAL · SOLUTION
partial-onset seizures in patients 1 month of ageolder
2016
NDA
35/100
COREG CR
carvedilol phosphate
Post-LOE
Viatris (2)
ORAL · CAPSULE, EXTENDED RELEASE
mild-to-severe chronic heart failure of ischemiccardiomyopathic origin+10
2006
NDA
35/100
NAPROXEN SODIUM
naproxen sodium
Post-LOE
ORAL · CAPSULE
2006
NDA
35/100
PRADAXA
dabigatran etexilate
Post-LOE
Boehringer Ingelheim
ORAL · PELLETS
venous thromboembolic events (VTE) in pediatric patients aged 3 months to less than 12 years of agerecurrence of VTE in pediatric patients aged 3 months to less than 12 years of age
2021
NDA
35/100
PRETOMANID
pretomanid
Post-LOE
Viatris (2)
ORAL · TABLET
2019
NDA
35/100
PRIMATENE MIST
epinephrine inhalation
Post-LOE
INHALATION · AEROSOL, METERED
2018
NDA
35/100
PROMACTA KIT
eltrombopag olamine
Post-LOE
Novartis
ORAL · FOR SUSPENSION
thrombocytopenia in adultolder with persistent+8
2015
NDA
35/100
REXTOVY
naloxone hydrochloride
Post-LOE
R-Pharm US
NASAL · SPRAY, METERED
2023
NDA
35/100
SKELAXIN
metaxalone
Post-LOE
Pfizer
ORAL · TABLET
1962
NDA
35/100